Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9100514 | 0.88 | PSMB5 (0.40) | S1PR1PSMB5PSMB8CTSBSLC6A3 | |
| SCHEMBL9104383 | 0.76 | S1PR1 (0.46) | ESR1ESR2S1PR1PSMB5PSMB8 | |
| SCHEMBL9107633 | 0.76 | SLC1A1 (0.44) | PSMB5PSMB8CTSBMEN1KMT2A | |
| SCHEMBL9108065 | 0.73 | PPARG (0.34) | S1PR1KMT2A | |
| SCHEMBL9108058 | 0.73 | PPARG (0.34) | S1PR1KMT2A | |
| SCHEMBL10069410 | 0.73 | SLC7A5 (0.46) | PSMB5PSMB8CTSBPTGS1PTGS2 | |
| SCHEMBL17739986 | 0.73 | PSMB5 (0.43) | PSMB5PSMB8CTSBCNR1MEN1 | |
| SCHEMBL3476279 | 0.72 | ESR1 (0.46) | ESR1ESR2CNR1 | |
| SCHEMBL15695424 | 0.72 | ESR1 (0.41) | ESR1ESR2S1PR1PSMB5PSMB8 | |
| SCHEMBL15695414 | 0.72 | ESR2 (0.41) | ESR1ESR2S1PR1PSMB5PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150231158-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2015-08-20 | — | — | US | disclosed |
| EP-2646018-B1 | NOVEL OXIME AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2646114-B1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140057878-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8609636-B2 | Oxime derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130310360-A1 | NOVEL OXIME AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518932-B2 | Oxime azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120142661-A1 | NOVEL OXIME AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142642-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231158-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | ESR1 1588/4885ESR2 791/4885S1PR1 1/4885 |
| US-20140057878-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | ESR1 1588/4885ESR2 791/4885S1PR1 1/4885 |
| US-20130310360-A1 | NOVEL OXIME AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR2, S1PR5 | ESR1 1467/4885ESR2 1189/4885S1PR1 1/4885 |
| US-20120142642-A1 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | ESR1 1588/4885ESR2 791/4885S1PR1 1/4885 |
| US-20120142661-A1 | NOVEL OXIME AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR2, S1PR5 | ESR1 1467/4885ESR2 1189/4885S1PR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.